Physician profile
Brian Simba
NPI 1023464435
$1,364.53
in general payments reported to CMS, 2019-2025
16 companies · $44.63 in 2025
The $44.63 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $476 · 2023: $247 · 2024: $489 · 2025: $44.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682 · Education: $98.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.56 |
| Education | $98.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.36 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $220.79 | 2022-2025 | Jynarque |
| Baxter Healthcare | $115.89 | 2023-2024 | Renal - Chronic, Renal - Pd |
| Amgen INC. | $112.68 | 2021-2024 | Tavneos, Parsabiv, Aranesp |
| Aurinia Pharma U.S., INC. | $98.97 | 2021-2023 | Lupkynis |
| Travere Therapeutics, INC. | $94.64 | 2023-2025 | Filspari |
| Ardelyx, INC. | $50.91 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $48.98 | 2023-2024 | |
| Akebia Therapeutics INC | $48.94 | 2022-2024 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.24 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $23.50 | 2024 | |
| Opko Pharmaceuticals, LLC | $22.13 | 2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $20.46 | 2024 | Velphoro |
| Medtronic, INC. | $20.31 | 2022 | |
| Calliditas Therapeutics US INC. | $18.41 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.32 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Simba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.